Is lipoprotein(a) the major carrier of oxidized phospholipids that promote vascular inflammation and plaque progression?

Lipoprotein(a) [Lp(a)] is established as the primary vehicle for transporting oxidized phospholipids (OxPL) in human circulation. This relationship is critical to understanding why elevated Lp(a) levels serve as a potent independent risk factor for cardiovascular disease beyond traditional lipid markers.

Transport and sequestration mechanisms

Lp(a) acts as a specialized reservoir for OxPL, sequestering the majority of these pro-inflammatory molecules compared to other lipoproteins like LDL.

• Molecular binding: OxPLs are primarily attached to the apolipoprotein(a) [apo(a)] component of the Lp(a) particle. This occurs via covalent and non-covalent binding at the lysine-binding sites within the kringle IV type 10 (KIV10) domain.
• Structural specificity: Mutations in the KIV10 domain can abolish the presence of detectable OxPLs on Lp(a), highlighting the highly specific nature of this transport role.
• Clinical confirmation: In patients undergoing lipoprotein apheresis, the targeted removal of Lp(a) results in a nearly proportional reduction in circulating OxPL levels, confirming that Lp(a) is the dominant carrier.

Promotion of vascular inflammation

Once transported to the vessel wall, the OxPLs carried by Lp(a) initiate a cascade of inflammatory processes.

• Macrophage activation: OxPLs interact with cellular receptors to drive the differentiation of pro-inflammatory M1-type macrophages. These cells secrete a range of cytokines, including IL-1β, IL-6, and TNF-α.
• Oxidation-specific epitopes: The OxPLs create specific molecular patterns that are recognized by the innate immune system, triggering an autoimmune-like inflammatory response within the arterial intima.

Plaque progression and clinical outcomes

The chronic inflammation driven by Lp(a)-bound OxPL directly accelerates the growth and instability of atherosclerotic plaques.

• Plaque dynamics: Evidence indicates that OxPLs promote the formation of lipid-protein adducts and oxysterols, leading to vascular cell apoptosis and increased intima-media thickening.
• Cardiovascular risk: High levels of OxPL on apolipoprotein B-100 (OxPL-apoB) are associated with significantly higher odds of multivessel coronary artery disease and major adverse cardiovascular events (MACE).
• Calcification: Beyond plaque, OxPL-apoB levels strongly correlate with the progression of calcific aortic valve disease, suggesting a systemic impact on vascular and valvular health.

Bottom line

Lp(a) is the major carrier of oxidized phospholipids, which serve as potent pro-inflammatory mediators. Through the activation of macrophages and the induction of cytokine cascades, these phospholipids drive vascular inflammation and atherosclerotic plaque progression, explaining much of the pathogenicity associated with elevated Lp(a).